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Angiotensin II Type 1 Receptor-Dependent
Oxidative Stress Mediates Endothelial Dysfunction
in Type 2 Diabetic Mice
Wing Tak Wong,1,2,* Xiao Yu Tian,1,2,* Aimin Xu,3 Chi Fai Ng,4 Hung Kay Lee,5 Zhen Yu Chen,6
Chak Leung Au,1,2 Xiaoqiang Yao,1,2 and Yu Huang1,2
Abstract
The mechanisms underlying the effect of the renin-angiotensin-aldosterone system (RAAS) inhibition on en-
dothelial dysfunction in type 2 diabetes are incompletely understood. This study explored a causal relationship
between RAAS activation and oxidative stress involved in diabetes-associated endothelial dysfunction. Daily
oral administration of valsartan or enalapril at 10mg=kg=day to db=db mice for 6 weeks reversed the blunted
acetylcholine-induced endothelium-dependent dilatations, suppressed the upregulated expression of angioten-
sin II type 1 receptor (AT1R) and NAD(P)H oxidase subunits (p22
phox and p47phox), and reduced reactive oxygen
species (ROS) production. Acute exposure to AT1R blocker losartan restored the impaired endothelium-
dependent dilatations in aortas of db=db mice and also in renal arteries of diabetic patients (fasting plasma
glucose level 7.0mmol=l). Similar observations were also made with apocynin, diphenyliodonium, or tempol
treatment in db=db mouse aortas. DHE fluorescence revealed an overproduction of ROS in db=db aortas
which was sensitive to inhibition by losartan or ROS scavengers. Losartan also prevented the impairment of
endothelium-dependent dilatations under hyperglycemic conditions that were accompanied by high ROS
production. The present study has identified an initiative role of AT1R activation in mediating endothelial
dysfunction of arteries from db=db mice and diabetic patients. Antioxid. Redox Signal. 13, 757–768.
Introduction
Type 2 diabetes mellitus is associated with an increasedrisk of cardiovascular complications (27). Although
the exact mechanisms are only partially understood, endo-
thelial dysfunction plays a critical role in the initiation and
progression of diabetic vascular diseases (15). The endothe-
lium is essential for the maintenance and regulation of vas-
cular homeostasis, by releasing both endothelium-derived
relaxing factors such as nitric oxide (NO) and contracting
factors such as reactive oxygen species (ROS). Endothelial
dysfunction due to a reduced NO bioavailability is one of
important early events in the development of hypertension,
diabetes, and atherosclerosis (8, 41). The degree of reduced
endothelium-derived NO predicts the severity of future vas-
cular events (42).
Elevated ROS production, which is manifest in hyperten-
sion, diabetes, and atherosclerosis, is also one of the major
initiators for endothelial dysfunction (8, 41) by direct inacti-
vation of endothelium-derived NO. It is thus of great impor-
tance to define and explore oxidative mechanisms involved in
endothelial dysfunction in type 2 diabetes (19). Sources of
endogenous ROS that cause endothelial dysfunction include
NAD(P)H oxidases (7) and endothelial nitric oxide synthase
(eNOS) uncoupling (31).
The role of the renin-angiotensin-aldosterone system
(RAAS) had been best defined in hypertension due to the
wide application of RAAS blockers for lowering blood pres-
sure. Of importance, existing evidence suggests a significant
role of a local RAAS in the vascular wall as a key negative
regulator of endothelial function in diabetes as well. Chronic
angiotensin converting enzyme (ACE) inhibition improves
endothelial function and cardiovascular outcomes in type 2
diabetic patients (14, 30, 32, 47). Apart from ACE inhibitors,
angiotensin receptor blockers (ARBs) are also effective in
improving cardiac function and reducing arterial stiffness in
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diabetic patients (4, 11, 16, 35, 44). Local and circulating an-
giotensin II (Ang II) is an important mediator of both meta-
bolic and vascular dysfunction in diabetes (6). Animal studies
also provided evidences for RAAS blockers in diabetes. ARB
improve vascular function in type I diabetic rat (2, 36). ARB
may ameliorate diabetic vasculopathy and nephropathy
through prevention of eNOS uncoupling (31, 34, 45). Ang II
binds to both Ang II type 1 (AT1R) and type 2 receptor (AT2R)
(43). Most known detrimental effects of Ang II in vasculature
are attributed to AT1R which is linked to NAD(P)H oxidase
activation and ROS production (21). Hyperglycemia also
upregulates the AT1R in vascular smooth muscle cells (37).
However, the functional implications and the precise intra-
cellular mechanisms by which AT1R activation and subse-
quent oxidative stress in diabetes that in turn impairs
vasodilatation are not thoroughly understood.
In the present study, we examine the hypotheses that the
upregulation of AT1R together with oxidative stress plays a
critical role in the induction and maintenance of endothelial
dysfunction in aortas of type 2 diabetic db=db mice and in
renal arteries from type 2 diabetic patients.
Materials and Methods
Animal model
All animal experiments were performed on type 2 diabetic
mice (C57BL=KSJ) lacking the gene encoding for leptin re-
ceptor (db=db) and heterozygote (db=mþ) control which were
supplied by Chinese University of Hong Kong (CUHK) La-
boratory Animal Service Center after an approval was ob-
tained from the Animal Experimentation Ethics Committee,
CUHK. Mice were kept in a temperature-controlled holding
room (228–248C) with a 12-h light=dark cycle, and fed a
standard diet and water ad libitum. At the age of 12 weeks,
adult male db=dbmice were treated for 6 weeks with valsartan
or enalapril at 10mg=kg body weight=day or vehicle via oral
gavage. Plasma glucose levels were determined using a blood
glucose meter (Ascenia ELITE XL, Bayer, IN). Systolic blood
pressure was measured by a tail-cuff method.
Human renal arteries
Human renal arteries were obtained during surgery after
informed consent from kidney cancer patients, aged between
56 and 82 years old, undergoing nephrectomy. One arterywas
obtained from each patient. The group of diabetic patients had
a fasting plasma glucose level7.0mmol=l (126mg=dl) or 2-h
plasma glucose 11.1mmol=L (200mg=dl).
Plasma lipid profile and insulin in mice
Plasma levels of total cholesterol and triglyceride were
determined using enzymatic methods (Stanbio, Boerne, TX)
and plasma insulin level was assayed by enzyme immuno-
assay (Mercodia, Uppsala, Sweden).
Isometric force measurement
After mice were sacrificed by CO2 inhalation, the thoracic
aortas were rapidly removed and placed in oxygenated ice-
cold Krebs–Henseleit solution. Changes in isometric tension
of vessels were recorded in aMultiMyograph System (Danish
Myo Technology, Aarhus, Denmark) as previously described
(24), and changes in isometric tension were recorded. The ring
was stretched to an optimal baseline tension of 3mN and then
allowed to equilibrate for 60min before the start of the ex-
periment. Each ring was first contracted by 60mmol=L KCl
and rinsed in Krebs solution, and after wash out, phenyl-
ephrine (1mmol=L) was used to produce a steady contraction
and relaxed by cumulative additions of acetylcholine (ACh)
(108 to 105 mol=L) in control or in the presence of 3 mmol=L
losartan (ARB), 100 mmol=L apocynin [NAD(P)H oxidases
inhibitor], or 100mmol=L tempol [superoxide dismutase
(SOD) mimetic]. These inhibitors had no effect on acetylcho-
line-induced relaxations in aortas from nondiabetic db=mþ
mice (data not shown). Endothelium-independent relaxations
to sodium nitroprusside (SNP) (109 to 106 mol=L) were
studied in rings without endothelium. Each experiment was
performed on rings prepared from different mice.
Each human renal artery was cut into 2–3 ring segments (2–
3mm in length) and each set of experiments were performed
on rings from different human samples. Rings were sus-
pended in organ baths as described previously (26). Each ring
was initially stretched to an optimal tension of 25mN and
then allowed to equilibrate for 90min before the start of the
experiment.
Detection of intracellular ROS
by dihydroethidium fluorescence
The amount of intracellular ROS production was deter-
mined using dihydroethidium (DHE) (Molecular Probes, Eu-
gene, OR), which binds to DNA when oxidized to emit
fluorescence (33). Aortic rings from db=mþ and db=dbmicewere
obtained as described above and treated with or without ACh.
To investigate the inhibitory effects of the RAAS inhibitor on
ROS production, aortas were exposed for 30min to one of the
inhibitors including losartan, apocynin, or tempol before the
addition of ACh, as to mimic the conditions in the functional
study. To verify the contribution of ROS production from en-
dothelium, the endothelial layer was removed by rolling the
luminal surfacewith the tip of a pair of fine forceps. To examine
the role of extracellular calcium ions on the generation of ROS,
calcium-free Krebs solutionwas prepared to incubate the aortic
rings for 30min before the addition of ACh. Frozen sections of
the aortic ring were cut in 10-mm thickness using cryostat and
incubated for 10min at 378C in Krebs solution containing
5mmol=L DHE. Fluorescent intensity was measured by con-
focal microscope (FV1000, Olympus, Tokyo, Japan) at excita-
tion=emission of 488=605nm to visualize the signal. The
images were analyzed by the Fluoview software (Olympus).
Immunohistochemical staining of Ang II
Aortic rings were fixed in 4% paraformaldehyde at 48C
overnight, dehydrated, processed, and embedded in paraffin.
Cross sections at 5 mm were cut on microtome (Leica Micro-
systems, Wetzlar, Germany). After rehydrated to water, sec-
tions were microwave boiled in 0.01mol=L citrate buffer (pH
6.0) for 10min for antigen retrieval, then incubated for 15min
with 3% H2O2 at room temperature to block endogenous
peroxidase activity. After washed with phosphate buffer
saline (PBS), sections were blocked in 5% normal goat or
donkey serum according to the host species ( Jackson Im-
munoresearch, West Grove, PA) for 1 h at room temperature.
Primary antibody (anti-Ang II, 1:500, Peninsula laboratory,
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Belmont, CA, and anti-eNOS, 1:200, Santa Cruz, CA) diluted
in normal serum were incubated overnight at 48C. The slides
were washed with PBS three times (5min each). Biotin-SP
conjugated goat anti-rabbit secondary antibodies (1:500,
Jackson Immunoresearch) diluted in PBS were added and
incubated for 1 h at room temperature. Slides were washed
with PBS three times (5min each) and incubated for 30min
with streptavidin-HRP conjugate (1:500, Zymed laboratory,
San Francisco, CA) at room temperature, and washed. Posi-
tive staining was developed as brown precipitate by 3,3’-
diamonobenzidine tetrachloride (DAB) chromogen substrate
(Vector laboratory, Burlingame, CA). Slides were rinsed with
water and counterstained with hematoxylin. Pictures were
taken under Leica DMRBE microscope with a SPOT-RT dig-
ital camera and SPOT Advanced software (Diagnostic In-
struments, Sertling Heights, MI) and intensities of signals
were analyzed by ImageJ (National Institute of Health,
Bethedsa, MD).
Western blot analysis
Protein samples prepared from aorta homogenates were
electrophoresed through a 10% SDS-poly-acrylamide gel,
transferred onto an immobilon-P polyvinylidene difluoride
membrane (Millipore Corp., Bedford, MA). Nonspecific
binding sites were blocked with 5% nonfat milk or 1% BSA in
0.05% Tween-20 PBS. The blots were incubated overnight at
48C with the primary antibodies: monoclonal anti-AT1R,
polyclonal anti-AT2R (1:1000, Abcam, Cambridge, UK);
monoclonal anti-nitrotyrosine (1:2000, Abcam), polyclonal
anti-phosphor-eNOS Ser1177 (1:1000, Upstate Biotechnology,
Lake Placid, NY); polyclonal anti-ACE, anti-eNOS, anti-
p22phox and anti-p47phox (1:1000, Santa Cruz); monoclonal
anti-phosphor-p38 MAPK (Thr180=Tyr182), polyclonal anti-
p38 MAPK, monoclonal anti-phospho-p44=42 MAPK
(ERK1=2) (Thr202=Tyr204), monoclonal anti-p44=42 MAPK
(Cell Signaling, Beverly, MA), followed by HRP-conjugated
Table 1. Basic Parameters in db=mþ Control, db=db, and db=db Mice Chronically Treated
with Valsartan or Enalapril
db=dbþ db=dbþ
Parameter db=mþ db=db Valsartan Enalapril
Body weight, g 26.6 1.5 55.7 1.7* 52.8 1.4* 55.7 2.8*
Blood pressure, mmHg 92.6 1.6 127.3 3.9* 102.6 4.3# 93.0 1.9#
Plasma level of Glucose (fasting), mmol=L 5.2 2.2 17.0 3.7* 14.0 1.6* 15.1 1.6*
Insulin, ng=mL 1.4 0.12 24.6 3.5* 26.2 4.4* 25.8 5.1*
Total cholesterol, mg=dl 75.7 2.4 133.1 6.4* 97.5 3.7# 113.9 5.3#
Triglyceride, mg=dl 86.5 5.2 184.3 15* 174.7 10* 166.3 13*
Results are means SEM of measurements from 6–8 different mice. *p< 0.05 relative to db=mþ group; #p< 0.05 relative to db=db group.
FIG. 1. Valsartan or enalapril
treatment improved endothelial
function in db=db mice. Chronic
treatment for 6 weeks with val-
sartan (AT1R blocker, 10mg=kg=
day) or enalapril (ACE inhibitor,
10mg=kg=day) improved endo-
thelial function, as shown by
representative records (A) and
concentration-response curves
(B, C). Data are means SEM; n¼
7–8; ***p< 0.001 relative to db=db.
Phe, phenylephrine.
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secondary antibody (DakoCytomation, Carpinteria, CA).
Monoclonal anti-b-actin (1:5000, Abcam) was used as a
housekeeping protein. Densitometry was performed using a
documentation program (Flurochem, Alpha Innotech Corp.,
San Leandro, CA).
Organ culture of mouse arterial rings in high
glucose medium
High glucose (30mmol=L) and mannitol (osmotic control)
solutions were prepared in Dulbeco’s Modified Eagle’s Media
(DMEM, Gibco, Gaithersberg, MD) culture media supple-
mented with 10% fetal bovine serum (FBS, Gibco), plus
100 IU=ml penicillin and 100 mg=ml streptomycin. Mouse
thoracic aortic rings (2mm in length) were then incubated in
four groups, including 5mmol=L glucose alone (NG),
5mmol=L glucose plus 25mmol=L mannitol (M), 30mmol=L
glucose (HG), 30mmol=L glucose plus 3 mmol=L losartan
(HGþ losartan) for 36 h in an incubator kept at 378C. After the
incubation period, the segments were transferred to fresh
Krebs solution, mounted in a myograph, and changes in
arterial tone were recorded.
Drugs and solutions
Acetylcholine, NG-nitro-L-arginine methyl ester (L-NAME),
phenylephrine, angiotensin II, sodium nitroprusside (SNP),
diphenyliodonium, and tempol were purchased from Sigma-
Aldrich Chemical (St Louis, MO). Apocynin was from Cal-
biochem (San Diego, CA). Losartan was purchased from
Cayman (Ann Arbor, MI). Besides losartan, apocynin and di-
phenyliodoniumwere dissolved in DMSO (Sigma-Aldrich), all
other drugs were dissolved in double-distilled water. Krebs
solution contained (mmol=L): 119 NaCl, 4.7 KCl, 2.5 CaCl2, 1
MgCl2, 25 NaHCO3, 1.2 KH2PO4, and 11 D-glucose. A Ca
2þ-
free solution was identical to Krebs solution with exclusion of
Ca2þ and addition of 2mmol=L EGTA.
Statistical analysis
Results were means SEM from different mice or human
subjects. Concentration-response curves were analyzed by
nonlinear regression curve fitting using GraphPad Prism soft-
ware (Version 4.0, San Diego, CA) to approximate Emax as the
maximal response and pIC50 as the negative logarithm of the
drug concentration that produced 50%of Emax. These values are
summarized in Supplemental Table 1 (see www.liebert
online.com=ars) for relaxant responses in both mouse and
human arteries. Statistical significance was determined by two-
tailed Student’s t-test or one-way ANOVA followed by
Bonferroni post-tests when more than two treatments were
compared. P< 0.05 was regarded as significantly different.
Results
Basic metabolic parameters
Body weight of db=dbmice increased gradually from 4 to 16
weeks when compared with age-matched db=mþ lean control
mice (Supplemental Fig. 1A; see www.liebertonline.com=ars).
Valsartan or enalapril treatment for 6 weeks did not alter body
weight of db=db mice (Table 1). Oral glucose tolerance test re-
vealed a progressive impairment in glucose sensitivity (Sup-
plemental Fig. 1B; see www.liebertonline.com=ars) in db=db
mice. The levels of fasting blood glucose and plasma insulin
were higher in db=db mice than db=mþ mice and these values
were unaffected by valsartan or enalapril treatment (Table 1).
However, treatment with valsartan and enalapril both im-
proved glucose tolerance (Supplemental Figs. 2A–2C; see
www.liebertonline.com=ars). Blood pressure of db=db mice
(127.3 3.9 mmHg, P< 0.05 vs db=mþ) was higher than that of
db=mþmice (92.6 1.6mmHg)whichwas reducedby valsartan
(102.6 4.3 mmHg, P< 0.05 vs db=db) or enalapril (93.0 1.9
mmHg, P< 0.05 vs db=db) treatment (Table 1 and Supplemental
FIG. 2. Blockade of RAAS and associated oxidative stress
improved endothelium-dependent dilatations in db=db
mouse aortas. (A) ACh-induced dilatations were impaired in
db=db (n¼ 6) compared with db=mþ mouse aortas; whilst (B)
SNP-induced endothelium-independent dilatation was com-
parable in both groups. Acute exposure of diabetic mouse
aortas to (C) losartan (3mmol=L, AT1R blocker), apocynin
(100mmol=L, NAD(P)H oxidase inhibitor), or tempol
(100mmol=L, ROS scavenger) enhanced ACh-induced dilata-
tions. Combined treatment with losartan and apocynin had no
further improvement (C). Data are means SEM; n¼ 6–8;
***p< 0.001 relative to db=mþ and *p< 0.05 relative to db=db.
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Fig. 2D; see www.liebertonline.com=ars). In addition, the ele-
vated levels of plasma triglyceride in db=db mice were insensi-
tive to valsartan or enalapril treatment. By contrast, valsartan or
enalapril treatment reversed the increased level of total cho-
lesterol in db=db mice (Table 1).
Improved endothelium-dependent dilatations in db=db
mouse aortas by RAAS blockade
Six-week chronic treatment with valsartan or enalapril
significantly improved endothelium-dependent dilatations in
db=dbmouse aortas as shown in representative tracings (Figs.
1A–1C). ACh-induced endothelium-dependent dilatations
were impaired in db=dbmouse aortas as compared with those
of nondiabetic db=mþ mice (Figs. 1A and 2A), whilst sodium
nitroprusside (SNP)-induced endothelium-independent dila-
tations were comparable between the two groups (Fig. 2B).
AT1R blockade by losartan (3mmol=L, 30-min incubation)
(Fig. 2C) and inhibition of NAD(P)H oxidases by apocynin
(100 mmol=L, Fig. 2C) improved ACh-induced vasodilata-
tions, whilst combination of losartan and apocynin (Fig. 2C)
did not cause further improvement (Supplemental Table 1).
SOD mimetic tempol (100 mmol=L, Fig. 2C) also enhanced the
blunted dilatations to ACh in db=db mouse aortas.
Augmented ROS production in db=db mouse aortas
mediated by AT1R
The basal level of ROS reflected by the intensity of di-
hydroethidium (DHE) fluorescence was much higher in the
wall of db=db mouse aortas (Fig. 3). The ROS level markedly
increased in response to ACh (10mmol=L), but to a greater
extent in db=db mouse aortas (Figs. 3A and 3B). Acute exposure
of db=db mouse aortas to L-NAME (100mmol=L) attenuated
ACh-stimulated rises in ROS. The increased ROS generation
was eliminated by 30-min treatment with losartan (3mmol=L),
apocynin (100mmol=L), or tempol (100mmol=L) (Figs. 3A and
3B). Furthermore, the ACh-stimulated ROS increase was
greatly diminished in the absence of extracellular Ca2þ ions or
in aortas without endothelium (Figs. 3A and 3B). Increased
ROS production in db=db mouse aortas was also abolished by
chronic valsartan or enalapril treatment (Figs. 3C and 3D).
Effects of RAAS blockade on local production of Ang II
in the vascular wall
Increased Ang II staining was observed in the vascular wall
of aortas from db=dbmice compared with db=mþ control (Figs.
4A and 4B), accompanied by ACE upregulation (Fig. 4C).
FIG. 3. AT1RmediatedROSproduction indb=dbmouse aortas. (A) Addition ofACh (þACh) increasedROSproduction in db=db
mouse aortas without an effect in nondiabetic mouse aortas. The ROS increase was inhibited by L-NAME, and eliminated by acute
exposure to losartan, apocynin, or tempol. ACh failed to trigger ROS increase in db=dbmouse aortaswithout endothelium (-Endo), or
with endothelium but in the absence of extracellular Ca2þ ions (-Ca2þ). (B) Summarized data of DHE fluorescence intensity under
different pharmacological interventions. (C, D) Chronic RAAS inhibition also prevented the increased ROS production in db=db
mouse aortas reflected by DHE fluorescence. Data are means SEM; n¼ 4- 6; *p< 0.05 relative to db=mþ -Ach; {p< 0.05 vs db=db –
Ach; #p< 0.05 relative to db=dbþACh. (For interpretation of the references to color in this figure legend, the reader is referred to the
web version of this article at www.liebertonline.com=ars).
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Chronic RAAS blockade normalized the ACE expression and
tissue Ang II levels (Figs. 4A–4C).
Western blot analysis of AT1R, AT2R, p22
phox,
p47phox, nitrotyrosine, eNOS, and p-eNOS
Immunoblotting showed that a significantly increased ex-
pression of AT1R in db=db mouse aortas was normalized by
valsartan or enalapril treatment (Fig. 5A) while AT2R ex-
pression remained unaffected (Supplemental Fig. 3B; see
www.liebertonline.com=ars). Ang II also induced a greater
vasoconstriction in db=db mouse aortas that were prevented
by valsartan or enalapril treatment (Supplemental Fig. 3C; see
www.liebertonline.com=ars). In addition, chronic therapy
with valsartan or enalapril reduced the increased level of
NAD(P)H oxidase subunits p22phox (Fig. 5B) and p47phox (Fig.
5C). The elevated nitrotyrosine levels in db=dbmouse aortas were
also reversed by the treatment with valsartan or enalapril (Fig.
5D). The reduced phosphorylation of eNOS at Ser1177 in db=db
mouse aortas could not be reversed by RAAS blockade, while
total eNOS protein expression remained unchanged (Supple-
mental Fig. 4; see www.liebertonline.com=ars).
Impaired endothelium-dependent relaxations
in renal arteries from diabetic patients rescued
by AT1R blockade
Renal arteries obtained from diabetic patients relaxed signif-
icantly less in response to ACh than those from nondiabetic
subjects (Figs. 6A and 6B). Acute exposure to losartan (3mmol=L)
for 30min markedly enhanced the ACh-induced relaxations in
diabetic human renal arteries (Fig. 6C) without affecting relax-
ations in nondiabetic human renal arteries (Fig. 6D). Renal ar-
teries from diabetic patients have significantly higher AT1R
expression as compared with those from nondiabetic control
(Fig. 6E, Supplemental Fig. 5; see www.liebertonline.com=ars).
FIG. 4. Enhanced angiotensin II production in diabetic aortic vascular wall prevented by chronic valsartan or enalapril treat-
ment. (A) Representative pictures showingAng II immunostaining inmouse aortas from db=mþ, db=db, db=db treatedwith valsartan,
and db=db treated with enalapril. eNOS immunostaining was used to show the endothelial layer. (B) Summarized figures for Ang II
staining in different groups of mice. (C) Western blot analysis demonstrating increased in angiotensin converting enzyme (ACE)
expression lowered by valsartan or enalapril chronic treatment. Data are means SEM of 4 experiments. Statistical significance is
indicatedby*p< 0.05 relative todb=mþ and#p< 0.05 relative todb=db. (For interpretationof the references to color in thisfigure legend,
the reader is referred to the web version of this article at www.liebertonline.com=ars).
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High glucose-induced endothelial dysfunction
mediated by AT1R
Chronic exposure (36 h) of nondiabetic mouse aortas to
high glucose (30mmol=L), but not to mannitol resulted in
impaired ACh-induced dilatations (Fig. 7A), whilst SNP-
induced endothelium-independent relaxations were unaf-
fected (Fig. 7B). The presence of losartan (3mmol=L) prevented
the impairment of ACh-induced dilatations in high glucose-
treated aortic rings (Fig. 7C). Likewise, losartan inhibited high
glucose-stimulated increase in ROS production in the aortic
wall (Fig. 7E). Losartan also restored ACh-induced dilatations
which were impaired by 12-h incubation with Ang II
(100 nmol=L) in nondiabetic mouse aortas (Fig. 7D).
Discussion
Our results clearly show a key role for AT1R-mediated ROS
overproduction in the diminished NO bioavailability which
accounts for the impairment of ACh-induced endothelium-
dependent dilatations in db=db mouse aortas. Chronic ad-
ministration of valsartan (ARB) or enalapril (ACE inhibitor) to
12-week old diabetic db=db mice prevents impaired endothe-
lium-dependent dilatations, which correlates with marked
downregulation of AT1R expression and reduction in ROS
production. Further supporting evidence comes from our
demonstration that acute exposure to inhibitors of RAAS-
oxidative stress axis (losartan, apocynin, or tempol) improves
endothelium-dependent dilatations in db=db mouse aortas
and inhibits the ACh-stimulated ROS production. Importantly,
losartan can also reverse the impaired endothelium-dependent
relaxations in renal arteries from patients with diabetes. To
further substantiate these findings, we also demonstrate that
losartan is able to reverse the impaired dilatation that is in-
duced by 36-h exposure of nondiabetic mouse aortas to high
glucose (30mmol=L); implicating that hyperglycaemia-
induced increase in ROS generation requires AT1R activation.
Taken together, the results of the present investigation support
and further define the critical role of AT1R as the therapeutic
target for alleviation of endothelial dysfunction and associated
vascular events in diabetes.
The effect of RAAS blockade has been tested in various
animal models of diabetes related vascular dysfunction. ACE
inhibitors such as perindopril, zofenopril, and enalapril can
prevent atherosclerosis progression in diabetic apoE-deficient
mice (10, 25) by decreasing Ang II and increasing bradykinin.
ACE inhibitors also restore vascular reactivity in type I dia-
betic mice (5). Likewise, ARBs such as candesartan, irbe-
sartan, and valsartan also showed effectiveness in attenuating
diabetes-associated atherosclerosis, retinopathy, and ne-
phropathy through inhibiting advanced glycation, oxidative
stress, and inflammatory cytokines (9, 10, 49). However, little
information is available concerning the functional benefit of
FIG. 5. RAAS inhibition attenu-
ated the upregulation of protein
expression of RAAS components.
(A) Upregulated AT1R (60 kDa) ex-
pression, elevated NAD(P)H oxi-
dases subunits p22phox (22kDa) (B),
and p47phox (47 kDa) (C), in diabetic
mouse aortas were normalized by
chronic treatment with valsartan or
enalapril. The increased nitrotyr-
osine (60 kDa) formation in db=db
mouse aortas was reduced by RAAS
inhibitors (D); n¼ 4; *p< 0.05 rela-
tive to db=mþ; #p< 0.05 relative to
db=db.
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RAAS blockade in blood vessels of db=db mice. Previous
clinical studies showed that AT1R blockade by losartan could
improve endothelial dilator function in patients with type 1
and type 2 diabetes (12, 13). However, whether this protective
effect is mediated through blood pressure-lowering effects or
other specific mechanisms is not clear. Flammer et al. reported
that losartan significantly improved endothelial function in
type 2 diabetic patients with hypertension, which might be
attributed to the antioxidative effect of ARB and was inde-
pendent of its blood pressure-lowering action, as serum 8-
isoprostane (a marker of oxidative stress) was significantly
lower in losartan group, regardless of blood pressure changes
(17). These results show the importance of antioxidative as-
pect of RAAS blockade that may contribute to the vasopro-
tection. While the correction of hypertension by ACE
inhibitors or ARBs may partly explain the observed im-
provement of endothelial function in db=dbmice, in the present
study, we intend to investigate whether AT1R blockers could
reverse the reduced vasodilatation in diabetic mice and dia-
betic patients through direct actions on the vascular wall.
The observation of impaired endothelium-dependent di-
latations in db=db mouse aortas is consistent with recently
reported results (29, 50). We conclude that AT1R mediates the
impaired vasodilatation in diabetes based on the following
observations. First, acute exposure of diabetic mouse aortas to
ARB significantly enhances ACh-induced dilatations. Acute
treatment with apocynin or tempol enhances the ACh-
induced dilatations to a similar extent. In addition, a combined
treatment with losartan and apocynin does not produce ad-
ditive effects, implicating that Ang II signaling involves se-
quential steps, initial stimulation of AT1R followed by
activation of NAD(P)H oxidases instead of independent ac-
tions. As apocynin was found to act as an antioxidant at
concentrations higher than 300mmol=L (1, 20), we used
100 mmol=L of apocynin in the present study. We have also
demonstrated that the enhanced ROS generation in mouse
aortas upon angiotensin II stimulation detected by DHE
fluorescence dye was prevented by both the NADPH oxidase
inhibitors while apocynin had no effect on hydrogen perox-
ide-stimulated ROS production (Supplemental Fig. 6; see
www.liebertonline.com=ars). Another structurally different
NADPH oxidase inhibitor diphenyliodonium at 0.1 mmol=L
also improved the impaired relaxations in db=db mouse
aortas and reduced angiotensin II-stimulated ROS generation
(Supplemental Fig. 7; see www.liebertonline.com=ars), fur-
ther supporting a role of NAD(P)H oxidase-derived ROS.
Second, losartan prevented the impaired vasodilatation and
ROS production in wild-type mouse arteries induced by high
glucose, indicating that a direct effect of hyperglycemia
on vasculature also requires AT1R activation. Finally, we
FIG. 6. Losartan improved
endothelial function in renal
arteries from diabetic pa-
tients. Representative records
for ACh-induced relaxations
of human renal arteries (A).
Endothelium-dependent re-
laxations were significantly
impaired in diabetic patients
(n¼ 5) as compared with
nondiabetic patients (n¼ 6)
(B). Acute exposure to lo-
sartan (3mmol=L) improved
the impaired ACh-induced
relaxations in diabetic human
renal arteries (n¼ 5) (C) with-
out affecting relaxations in
nondiabetic renal arteries (D).
Upregulation of AT1R ex-
pression in renal arteries from
diabetic patients as compared
to nondiabetic control (E).
Data are means SEM. ***p<
0.001 relative to nondiabetic;
**p< 0.01 relative to control.
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demonstrated that Ang II impaired vasodilatation which was
inhibited by losartan. To show the specificity of losartan on
AT1R instead of possible ROS scavenging activity, the con-
centration (3mmol=L) of losartan used in the functional study
does not scavenge ROS generated by xanthine oxidase as in-
dicated by electron paramagnetic resonance spectroscopy
(Supplemental Fig. 8; see www.liebertonline.com=ars).
Moreover, the reversal effect of losartan on high glucose-
induced ROS overproduction is novel and this effect may help
to elucidate more precise role of AT1R in hyperglycemia-
associated endothelial dysfunction in diabetes.
Chronic oral treatment with valsartan or enalapril
markedly improves endothelium-dependent dilatations of
db=db mouse aortas. It is postulated that ROS derived from
AT1R-mediated NAD(P)H oxidases lowers the bioavailabil-
ity of NO by either directly scavenging NO or by reducing
FIG. 7. Losartan prevented high glucose-induced endothelial dysfunction in nondiabetic mouse aortas. (A) Exposure to
30mmol=L high glucose (HG) for 36h reduced endothelium-dependent dilatations as compared with normal glucose
(5mmol=L, NG) or mannitol (25mmol=L mannitol plus 5mmol=L glucose). (B) SNP-induced endothelium-independent dila-
tations were the same between the NG and HG groups. (C) Co-treatment with losartan (3mmol=L) significantly restored the
impaired endothelial function. (D) Treatment with Ang II (100nmol=L) impaired endothelium-dependent dilatations that were
prevented by co-treatment with 3mmol=L losartan. Data are means SEM; n¼ 6–8. Statistical significance between groups is
indicated by **p< 0.01. (E, F) DHE fluorescence showed that high glucose enhanced ROS production in mouse aortas and
losartan (3mmol=L) blocked such effect (n¼ 4); *p< 0.05 relative to NG. #p< 0.05 relative to HG. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com=ars).
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the biosynthesis of NO catalyzed by endothelial nitric oxide
synthase (eNOS). Our immunoblotting results clearly show
that significant upregulations of AT1R and NAD(P)H oxi-
dase subunits (p22phox and p47phox) in db=db mouse aortas
can be normalized by chronic treatment with valsartan or
enalapril, suggesting that RAAS blockade suppresses the
stimulatory effect of Ang II on the expression and activity of
NAD(P)H oxidases. NAD(P)H oxidase is the major source
of ROS generation stimulated by Ang II, which is composed
by membrane-bound gp91phox homolog (NOX1 in vascular
smooth muscle cells and NOX2 in endothelial cells), cata-
lytic subunit p22phox, and regulatory subunits such as
p47phox, p40phox, p67phox, and Rac1 (3, 28). In addition, the
activation of p38 and extracellular signal-regulated kinase
(ERK) 1=2 mitogen-activated protein kinase (MAPK) in
db=db mouse aortas was also inhibited by RAAS blockade
(Supplemental Fig. 6). ROS stimulate the activation of
MAPK pathways which further promote the expression of
proinflammatory cytokines in endothelial cells (40), and
ARBs can ameliorate diabetic glomerulopathy by suppres-
sing MAPK activation (46). The inhibition of MAPK by
RAAS blockade may also offer additional benefit in db=db
mice. In contrast, RAAS blockade did not reverse the re-
duced phosphorylation of eNOS at Ser1177 in db=db mouse
aortas (Supplemental Fig. 4), implicating that chronic RAAS
blockade increased NO bioavailability by reducing oxida-
tive stress rather than enhancing the NO production from
eNOS (Supplemental Fig. 4). Although eNOS phosphoryla-
tion is known to decrease with prolonged oxidative stress
(23), Ang II is reported to exert different effects, either in-
creasing or decreasing eNOS phosphorylation (38, 39, 48).
However, we observed that RAAS blockade does not affect
eNOS phosphorylation. The present findings further sup-
port the primary role of RAAS-dependent oxidative stress in
endothelial dysfunction in diabetic mice.
The overproduction of ROS in diabetic mouse aortas, as
reflected by increases in nitrotyrosine formation and DHE
fluorescence intensity, is reversed by RAAS blockade. Similar
to previous findings of eNOS uncoupling in diabetes (22, 31),
we also confirmed this by showing that ACh stimulates fur-
ther increase of ROS only in diabetic but not in nondiabetic
mouse aortas, which is blocked by L-NAME or endothelium
removal. More relevantly, we demonstrate that blockade of
RAAS and associated oxidative stress by losartan, apocynin,
or tempol, greatly reduces the ROS production upon stimu-
lation of ACh. These results indicate that ROS derived from
NAD(P)H oxidases is likely required for stimulation of eNOS
uncoupling to further increase intracellular ROS generation.
In addition, we show that the release of ROS was dependent
on the presence of extracellular Ca2þ ions which is in accor-
dance with Guzik et al. who showed Ca2þ as an important
intracellular activator of NAD(P)H oxidases (18).
More significantly, we demonstrate a critical role of AT1R-
mediated ROS in impaired endothelium-dependent dilata-
tions of human renal arteries. Renal arteries from diabetic
patients have higher AT1R expression than nondiabetic con-
trol. Similar to db=dbmouse aortas, the impaired dilatations in
human arteries from diabetic patients can also be effectively
rescued by acute treatment with losartan, thus favoring the
use of AT1R blockers for reversing endothelial dysfunction in
patients with diabetes. In summary, the present study has
provided scientific basis with novel evidence in support of
clinical application of selective AT1R blockers for the pre-
vention and treatment of diabetes-related vascular dysfunc-
tion.
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